Impentamine dihydrobromide

Discontinued Product

Impentamine dihydrobromide (Cat. No. 1858) has been withdrawn from sale for commercial reasons.
Cat.No. 1858 - Impentamine dihydrobromide | C8H15N3.2HBr | CAS No. 149629-70-9
Description: Selective H3 antagonist
Alternative Names: VUF 4702
Chemical Name: 4-(5-Aminopentyl)imidazole dihydrobromide
Datasheet
Citations
Reviews
Literature (4)

Biological Activity for Impentamine dihydrobromide

Impentamine dihydrobromide is a potent and highly selective histamine H3 receptor antagonist (pA2 = 8.4); displays > 30000-fold selectivity over H1 and H2 receptors. Can act as a partial agonist in SK-N-MC cells expressing human H3 receptors. Produces antinociception, possibly via a non-H1, -H2 or -H3 receptor-mediated mechanism, following central administration in vivo.

Technical Data for Impentamine dihydrobromide

M. Wt 315.05
Formula C8H15N3.2HBr
Storage Desiccate at RT
CAS Number 149629-70-9
PubChem ID 53439849
InChI Key QSDXAAWBBPWGEL-UHFFFAOYSA-N
Smiles Br.Br.NCCCCCC1=CN=CN1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for Impentamine dihydrobromide

References for Impentamine dihydrobromide

References are publications that support the biological activity of the product.

Hough et al (1999) Antinociceptive activity of impentamine, a histamine congener, after CNS administration. Life Sci. 64 PL79 PMID: 10072195

Vollinga et al (1995) Homologs of histamine as histamine H3 receptor antagonists: a new potent and selective H3 antagonist, 4(5)-(5-aminopentyl)-1H-imidazole. J.Med.Chem. 38 266 PMID: 7830269

Wieland et al (2001) Constitutive activity of histamine H3 receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H3 antagonists. J.Pharmacol.Exp.Ther. 299 908 PMID: 11714875

View Related Products by Target

View Related Products by Product Action

View all Histamine H3 Receptor Antagonists

Keywords: Impentamine dihydrobromide, Impentamine dihydrobromide supplier, Selective, H3, antagonists, Receptors, Histamine, histaminergic, VUF4702, VUF, 4702, 1858, Tocris Bioscience

Citations for Impentamine dihydrobromide

Citations are publications that use Tocris products.

Currently there are no citations for Impentamine dihydrobromide.

Reviews for Impentamine dihydrobromide

There are currently no reviews for this product. Be the first to review Impentamine dihydrobromide and earn rewards!

Have you used Impentamine dihydrobromide?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Histamine Receptors

Histamine Receptors Scientific Review

Written by Iwan de Esch and Rob Leurs, this review provides a synopsis of the different histamine receptor subtypes and the ligands that act upon them; compounds available from Tocris are listed.

Alzheimer's

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.

Asthma

Asthma Poster

Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. This poster highlights key pathways and new therapies used to treat the condition, including those currently in clinical development.